Sandbox Reserved 1160: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
=== Ionic Locks === | === Ionic Locks === | ||
Another important structural feature is the series of <scene name='72/721531/Ionic_lock/5'>ionic locks</scene> on the intracellular side of the protein. Interactions between these five amino acids will form a salt bridge, which will stabilize the inactive conformation<ref name="Dore" />. The primary ionic lock forms between Glu770, Lys665, and Ser613<ref name="Dore" />. A secondary ionic lock occurs between Ser614 and Arg668<ref name="Dore" />. The purpose of these ionic locks is analogous to the ionic interactions that stabilize the T state in [[Hemoglobin]]. In the case of the TMD of mGlu5, the ionic lock is formed when the NAM mavoglurant is bound. | Another important structural feature is the series of <scene name='72/721531/Ionic_lock/5'>ionic locks</scene> on the intracellular side of the protein. Interactions between these five amino acids will form a salt bridge, which will stabilize the inactive conformation<ref name="Dore" />. The primary ionic lock forms between Glu770, Lys665, and Ser613<ref name="Dore" />. A secondary ionic lock occurs between Ser614 and Arg668<ref name="Dore" />. The purpose of these ionic locks is analogous to the ionic interactions that stabilize the T state in [[Hemoglobin]]. In the case of the TMD of mGlu5, the ionic lock is formed when the NAM mavoglurant is bound. These <scene name='72/721531/Ionic_lock/5'>ionic locks</scene> stabilize the inactive state, where the intracellular loops are stabilized facing inwards<ref name="Wu" />. This conformational change will effectively block the crevice that is involved in binding the G-protein<ref name="Wu" />. Models have suggested that, even in a glutamate bound state, the mavoglurant bound receptor would be dimerized but incapable of signaling<ref name="Wu" />. This signaling incapable mGlu5 dimer will help maintain the readiness of the pathway, while still decreasing signal response. | ||
== Disease == | == Disease == | ||